Vol 9, No 2 (2023)
Review paper
Published online: 2023-06-15

open access

Page views 512
Article views/downloads 279
Get Citation

Connect on Social Media

Connect on Social Media

Everything you always wanted to know about systemic sclerosis but were afraid to ask: Part 2. Intermediate pathophenotypes the best pathogenetic background in systemic sclerosis

Olga Gumkowska-Sroka12, Ewa Skotalczyk2, Monika Bultrowicz3, Magdalena Kopeć-Medrek13, Barbara Buc-Piorun3, Klaudia Palka3, Karolina Nowak3, Przemysław Kotyla123
Rheumatology Forum 2023;9(2):73-80.

Abstract

Systemic sclerosis (SSc, scleroderma) is a chronic systemic connective tissue disease with a complex pathogenesis that is still not fully understood, in the course of which attention is increasingly drawn to the dynamic, sequential pathogenetic mechanisms according to disease stage. An increasing understanding of the diversity of mechanisms underlying this disease, as well as the prevalence of certain pathogenetic elements that depend i.a. on disease stage, will enable more effective therapeutic interventions in the future. Systemic sclerosis can thus be seen as a complex process, where the main players are immune cells, endothelial cells and fibroblasts, and the focal point is probably impaired function and subsequent damage to endothelial cells. Systemic sclerosis is also the final stage of a certain continuum of events, starting with a state of susceptibility to the development of the disease (dependent on genetic conditions and environmental influences), followed by disruption of homeostasis and initiation of pathological processes (e.g. as a result of viral infections), progression of pathological responses (inflammation, endothelial damage, fibrosis) and consequently organ damage. According to most authors, the key event and focal point of the cascade of phenomena is endothelial cell damage, and the mechanisms that lead to this damage are related to the activation of the immune system. There is growing acceptance of the thesis of an autoimmune origin of the disease involving mechanisms of innate and acquired immunity, both cellular and humoral.

Article available in PDF format

View PDF Download PDF file

References

  1. Ptak W, Ptak M, Szczepanik M. Mechanizmy odporności nieswoistej. In: Podstawy immunologii. Wydawnictwo Lekarskie PZWL, Warszawa 2017: 113–134.
  2. Dowson C, Simpson N, Duffy L, et al. Innate immunity in systemic sclerosis. Curr Rheumatol Rep. 2017; 19(1): 2.
  3. Henderson NC, Rieder F, Wynn TA. Fibrosis: from mechanisms to medicines. Nature. 2020; 587(7835): 555–566.
  4. Varga J, Pasche B. Transforming growth factor beta as a therapeutic target in systemic sclerosis. Nat Rev Rheumatol. 2009; 5(4): 200–206.
  5. Stifano G, Affandi AJ, Mathes AL, et al. Chronic Toll-like receptor 4 stimulation in skin induces inflammation, macrophage activation, transforming growth factor beta signature gene expression, and fibrosis. Arthritis Res Ther. 2014; 16(4): R136.
  6. Farina A, Peruzzi G, Lacconi V, et al. Epstein-Barr virus lytic infection promotes activation of Toll-like receptor 8 innate immune response in systemic sclerosis monocytes. Arthritis Res Ther. 2017; 19(1): 39.
  7. Ciechomska M, Huigens CA, Hügle T, et al. Toll-like receptor-mediated, enhanced production of profibrotic TIMP-1 in monocytes from patients with systemic sclerosis: role of serum factors. Ann Rheum Dis. 2013; 72(8): 1382–1389.
  8. Luo JY, Liu X, Jiang M, et al. Oxidative stress markers in blood in systemic sclerosis: A meta-analysis. Mod Rheumatol. 2017; 27(2): 306–314.
  9. Zhang Y, Choksi S, Chen K, et al. ROS play a critical role in the differentiation of alternatively activated macrophages and the occurrence of tumor-associated macrophages. Cell Res. 2013; 23(7): 898–914.
  10. Henderson J, O'Reilly S. Inflammasome lights up in systemic sclerosis. Arthritis Res Ther. 2017; 19(1): 205.
  11. Ryu C, Walia A, Ortiz V, et al. Bioactive plasma mitochondrial DNA is associated with disease progression in scleroderma-associated interstitial lung disease. Arthritis Rheumatol. 2020; 72(11): 1905–1915.
  12. Frantz C, Pezet S, Avouac J, et al. Soluble CD163 as a potential biomarker in systemic sclerosis. Dis Markers. 2018; 2018: 8509583.
  13. Khanna D, Denton CP, Jahreis A, et al. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. Lancet. 2016; 387(10038): 2630–2640.
  14. Huang J, Maier C, Zhang Y, et al. Nintedanib inhibits macrophage activation and ameliorates vascular and fibrotic manifestations in the Fra2 mouse model of systemic sclerosis. Ann Rheum Dis. 2017; 76(11): 1941–1948.
  15. Kania G, Rudnik M, Distler O. Involvement of the myeloid cell compartment in fibrogenesis and systemic sclerosis. Nat Rev Rheumatol. 2019; 15(5): 288–302.
  16. Ah Kioon MD, Tripodo C, Fernandez D, et al. Plasmacytoid dendritic cells promote systemic sclerosis with a key role for TLR8. Sci Transl Med. 2018; 10(423).
  17. Wohlfahrt T, Usherenko S, Englbrecht M, et al. Type 2 innate lymphoid cell counts are increased in patients with systemic sclerosis and correlate with the extent of fibrosis. Ann Rheum Dis. 2016; 75(3): 623–626.
  18. Roan F, Stoklasek TA, Whalen E, et al. CD4+ group 1 innate lymphoid cells (ILC) form a functionally distinct ILC subset that is increased in systemic sclerosis. J Immunol. 2016; 196(5): 2051–2062.
  19. Hams E, Armstrong ME, Barlow JL, et al. IL-25 and type 2 innate lymphoid cells induce pulmonary fibrosis. Proc Natl Acad Sci U S A. 2014; 111(1): 367–372.
  20. Beon M, Harley RA, Wessels A, et al. Myofibroblast induction and microvascular alteration in scleroderma lung fibrosis. Clin Exp Rheumatol. 2004; 22(6): 733–742.
  21. Distler O, Distler JHW, Scheid A, et al. Uncontrolled expression of vascular endothelial growth factor and its receptors leads to insufficient skin angiogenesis in patients with systemic sclerosis. Circ Res. 2004; 95(1): 109–116.
  22. Eloranta ML, Franck-Larsson K, Lövgren T, et al. Type I interferon system activation and association with disease manifestations in systemic sclerosis. Ann Rheum Dis. 2010; 69(7): 1396–1402.
  23. Wu M, Assassi S. The role of type 1 interferon in systemic sclerosis. Front Immunol. 2013; 4: 266.
  24. Sato S, Fujimoto M, Hasegawa M, et al. Altered B lymphocyte function induces systemic autoimmunity in systemic sclerosis. Mol Immunol. 2004; 41(12): 1123–1133.
  25. Matsushita T, Hamaguchi Y, Hasegawa M, et al. Decreased levels of regulatory B cells in patients with systemic sclerosis: association with autoantibody production and disease activity. Rheumatology (Oxford). 2016; 55(2): 263–267.
  26. O'Reilly S, Hügle T, van Laar JM. T cells in systemic sclerosis: a reappraisal. Rheumatology (Oxford). 2012; 51(9): 1540–1549.
  27. Fuschiotti P. T cells in SSc skin lesions: knowing your enemy. Nat Rev Rheumatol. 2020; 16(5): 253–254.
  28. Kaviratne M, Hesse M, Leusink M, et al. IL-13 activates a mechanism of tissue fibrosis that is completely TGF-beta independent. J Immunol. 2004; 173(6): 4020–4029.
  29. Zhu Z, Homer RJ, Wang Z, et al. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J Clin Invest. 1999; 103(6): 779–788.
  30. Lee CG, Homer RJ, Zhu Z, et al. Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor beta(1). J Exp Med. 2001; 194(6): 809–821.
  31. Maehara T, Kaneko N, Perugino CA, et al. Cytotoxic CD4+ T lymphocytes may induce endothelial cell apoptosis in systemic sclerosis. J Clin Invest. 2020; 130(5): 2451–2464.
  32. Taylor DK, Mittereder N, Kuta E, et al. T follicular helper-like cells contribute to skin fibrosis. Sci Transl Med. 2018; 10(431).
  33. Parel Y, Aurrand-Lions M, Scheja A, et al. Presence of CD4+CD8+ double-positive T cells with very high interleukin-4 production potential in lesional skin of patients with systemic sclerosis. Arthritis Rheum. 2007; 56(10): 3459–3467.
  34. Johnson ME, Franks JM, Cai G, et al. Microbiome dysbiosis is associated with disease duration and increased inflammatory gene expression in systemic sclerosis skin. Arthritis Res Ther. 2019; 21(1): 49.